Bempegaldesleukin Plus nivolumab
The combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) was granted a breakthrough therapy designation by the FDA for the treatment of patients with previously untreated unresectable or metastatic melanoma.
The combination of bempegaldesleukin and nivolumab led to an overall response rate (ORR) of 53% by independent radiology review, which included a 34% complete response (CR) rate, in this patient population in a cohort of the ongoing phase I/II PIVOT-02 trial, which is the basis for the FDA deisgination.
Bempegaldesleukin is an investigational CD122-preferential interleukin-2 pathway agonist that is developed to activate and proliferate CD8+ effector T cells and natural killer cells.
Passing this along,
Missy
